Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT02891954
PHASE1

Genetics of Response to Canagliflozin

Sponsor: University of Maryland, Baltimore

View on ClinicalTrials.gov

Summary

Five daily doses of canagliflozin (300 mg) will be administered to healthy volunteers. Pharmacodynamic responses to canagliflozin will be assessed both at 2 days and 6 days after administration of the first dose of canagliflozin. A genome-wide association study (GWAS) will be conducted to search for genetic variants that are associated with each of the pharmacodynamic responses to canagliflozin.

Official title: Pharmacogenomics to Predict Responses to SGLT2 Inhibitors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

700

Start Date

2016-09

Completion Date

2026-12-25

Last Updated

2025-12-18

Healthy Volunteers

Yes

Interventions

DRUG

Canagliflozin

Healthy volunteers will receive canagliflozin (300 mg per day) in the morning for five days.